Drug Profile
Research programme: dendritic cell vaccine - DCPrime/Johnson & Johnson Innovative Medicine
Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator DCPrime; Janssen Pharmaceuticals
- Developer DCPrime; Johnson & Johnson Innovative Medicine
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 21 Dec 2020 DCPrime has been acquired by Immunicum
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in Netherlands (Parenteral)